A seven-year-old girl in the US with an aggressive form of childhood leukaemia has been cured using her own re-engineered immune cells, thanks to an experimental new therapy. Once the treatment had been carried out, the girls's doctors could find no evidence of any remaining cancer.
The girl, Emily, was the first child patient on a clinical trial that is testing T cell therapy to treat acute lymphoblastic leukaemia, as well as other B cell cancers. B cells are the type of White blood cell that becomes cancerous in some leukaemias and lymphomas.
In the trial, known as CTL019, Emily received a custom-designed version of her own T cells, which then rapidly multiplied and destroyed the leukaemia cells. The T cells, which do the job of recognising and attacking invading pathogens, were taken from the girl before being genetically modified by the researchers. They were modified to express a protein that binds to a target called CD19, a protein found on the surface of all B cells, including the cancerous ones. Normally, B cells are capable of remaining undetected by T cells, but the genetic modification makes them able to detect and destroy the cancerous B cells.
The modified T cells were then put back into the patient where they disperse and go in search of cancerous B cells. They also multiply at a rate that allows them to stay on top of the rapidly-dividing cancer cells, and stay in the body to continue fighting any new cancerous cells.
The team hopes that CTL019 will prove an effective therapy for patients with B cell cancers, but because only 12 patients took part in the trial, more adult and paediatric patients need to be enrolled to see if the same results are seen in a larger group.
Jack

No comments:
Post a Comment